1. Home
  2. DUO vs XTLB Comparison

DUO vs XTLB Comparison

Compare DUO & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DUO
  • XTLB
  • Stock Information
  • Founded
  • DUO 2011
  • XTLB 1993
  • Country
  • DUO China
  • XTLB Israel
  • Employees
  • DUO N/A
  • XTLB N/A
  • Industry
  • DUO Real Estate
  • XTLB Biotechnology: Pharmaceutical Preparations
  • Sector
  • DUO Finance
  • XTLB Health Care
  • Exchange
  • DUO Nasdaq
  • XTLB Nasdaq
  • Market Cap
  • DUO 17.1M
  • XTLB 16.3M
  • IPO Year
  • DUO 2019
  • XTLB 2005
  • Fundamental
  • Price
  • DUO $0.61
  • XTLB $1.66
  • Analyst Decision
  • DUO
  • XTLB
  • Analyst Count
  • DUO 0
  • XTLB 0
  • Target Price
  • DUO N/A
  • XTLB N/A
  • AVG Volume (30 Days)
  • DUO 2.0M
  • XTLB 14.5K
  • Earning Date
  • DUO 08-30-2024
  • XTLB 02-21-2025
  • Dividend Yield
  • DUO N/A
  • XTLB N/A
  • EPS Growth
  • DUO N/A
  • XTLB N/A
  • EPS
  • DUO N/A
  • XTLB N/A
  • Revenue
  • DUO $37,352,654.00
  • XTLB $46,000.00
  • Revenue This Year
  • DUO N/A
  • XTLB N/A
  • Revenue Next Year
  • DUO N/A
  • XTLB N/A
  • P/E Ratio
  • DUO N/A
  • XTLB N/A
  • Revenue Growth
  • DUO 6.61
  • XTLB N/A
  • 52 Week Low
  • DUO $0.32
  • XTLB $0.77
  • 52 Week High
  • DUO $4.67
  • XTLB $4.99
  • Technical
  • Relative Strength Index (RSI)
  • DUO 46.04
  • XTLB 40.75
  • Support Level
  • DUO $0.53
  • XTLB $1.62
  • Resistance Level
  • DUO $0.62
  • XTLB $1.85
  • Average True Range (ATR)
  • DUO 0.05
  • XTLB 0.23
  • MACD
  • DUO 0.00
  • XTLB -0.03
  • Stochastic Oscillator
  • DUO 43.82
  • XTLB 18.18

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About XTLB XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Share on Social Networks: